New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

Slides:

Advertisements

Similar presentations

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

Advertisements

LEADER trial: Primary Outcome

New Insights from EXSCEL

Cycloset®A Dopamine Receptor Agonist Cycloset® -Bromocriptine: Safety Trial: Post Hoc Analysis of Cumulative Percent MACE Endpoint Bromocriptine (Parlodel)

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Updates on Emerging GLP-1 Receptor Agonists

Updates on CVOT Data and Clinical Comparisons That Matter

Global Projections for Diabetes:

Insulin/GLP-1 Agonist Combinations

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Select Topics in Cardiovascular Medicine

Managing Complex Hypertension: What Every Physician Should Know

Updates on Outcomes for Novel T2D Therapies

SGLT2 Inhibitors in Phase 3 Trials

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Examining CV Effects of Basal Insulin Therapy

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Antithrombotics and PAD: A New Paradigm in Practice

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Emerging CVOT Data and Clinical Application

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Impacting CV Risk With Diabetes Medications

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Impacting CV Risk With Diabetes Medications

Clinical Application of New CV Outcomes Data

T2DM and CV Outcomes Trials: A Deep Dive!

A Deep Dive Into CVOTs.

Diabetes Increases Risk of CVD

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?

Tackling CV Risk in T2DM.

Insulin/GLP-1 Agonist Combinations

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Antihyperglycemic Therapy

CV Outcomes and Adherence With GLP-1 RAs

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Updates From ACC.

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Improving Overall Health

Are All Novel Insulins Proven to Be Equally Safe?

Deep Dive: Examining Emerging GLP-1 RAs From a Clinical Perspective

2015 EASD In Review: CV Risk management in t2dm

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Completed and ongoing CVOTs (6–14,39,44–58)

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.

Presentation transcript:

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

Introduction/Background

Prevalence Rates of CV Comorbidities in Persons With T2DM: Results of a Systematic Literature Review

Type 2 Diabetes and Cardiovascular Disease: Glucose-Plus Approach

Several Pathophysiologic Targets in T2DM

Pharmacologic Therapy for T2DM: ADA/EASD 2018 Recommendations

New Paradigm for Treating the Patient With Both T2DM and CVD

Decision Plan for Patient-Centered Glycemic Management in Type 2 Diabetes

Molecular Structure: GLP-1, Liraglutide, Dulaglutide, Albiglutide, Exenatide, Lixisenatide, and Semaglutide

Pleiotropic Effects of Selected GLP-1 RAs: Liraglutide and the LEADER Trial

Integrated Analysis of 6 DURATION Trials: Exenatide Once Weekly

Albiglutide: HARMONY Clinical Trial Program

Dulaglutide Clinical Program: HbA1c Change From Baseline Across Various Trials

Dulaglutide Clinical Program: Weight Change From Baseline Across Various Trials

Results From SUSTAIN 1-5: Change in HbA1c

Results From SUSTAIN 1-5: Change in Body Weight

SUSTAIN 7: Changes in HbA1c and Body Weight, Semaglutide vs Dulaglutide

Primary Endpoint Results From the LEADER Trial *

EMPA-REG OUTCOME: Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

HARMONY OUTCOMES Primary Endpoint Results: Time to CV Death, MI or Stroke (MACE)

LEADER: Results for CV Death

SUSTAIN-6 (Semaglutide): Primary Outcome Results

REWIND: Dulaglutide Topline Results

Sodium Salcaprozate (SNAC, sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) Oral Absorption Promoter

PIONEER 2 and 3 Topline Results

PIONEER 6: Topline Results For Cardiovascular Outcomes

Summary and Conclusions

Abbreviations

Abbreviations (cont)